🔒
Price chart and 15 days of daily prices
Candlestick chart with moving averages, Bollinger bands and MACD.
Register free to view.
Security Profile
- Security Type
- Common Stock
- CUSIP
- 74373P108
- Market Cap
- Small Cap · $108 Million
Business: Provectus Biopharmaceuticals, Inc. specializes in developing oncology and dermatology therapies. Its novel oncology drug PV-10 is designed to selectively target and destroy cancer cells without harming surrounding healthy tissue, significantly reducing systemic side effects. Its oncology focus is on melanoma, breast cancer and metastatic cancers of the liver.
Notes: June 24, 2015 -- announced today that it has completed its public offering of 17,500,000 shares of common stock and warrants to purchase 17,500,000 shares of common stock at a price to the public of $0.75 for a fixed combination of one share of common stock and a warrant to purchase one share of common stock. The warrants issued in the public offering began trading on the NYSE MKT under the ticker symbol PVCTWS on June 22, 2015. At this time, only warrants issued in the public offering are listed on NYSE MKT. Such warrants have an exercise price of $0.85 per share, are exercisable immediately and will expire on June 19, 2020.
Company Contact
- CEO
- Craig Dees, Ph.D.
- CFO
- Peter R. Culpepper
- Headquarters
- 7327 Oak Ridge Highway, Suite A, Knoxville, TN 37931
- Phone
- 866-594-5999 · Toll-Free 866-594-5999
- Fax
- 866-998-0005
- Investor Relations
- Marlon A. Nurse, Porter, LeVay & Rose, Inc. · 212-564-4700 · marlon@plrinvest.com